181 related articles for article (PubMed ID: 35200599)
1. Treatment Access, Health Economics, and the Wave of a Magic Wand.
Stewart DJ; Bradford JP; Batist G
Curr Oncol; 2022 Feb; 29(2):1176-1189. PubMed ID: 35200599
[TBL] [Abstract][Full Text] [Related]
2. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
[TBL] [Abstract][Full Text] [Related]
3. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
Rawson NSB; Stewart DJ
Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.
Foroutan N; Tarride JE; Xie F; Mills F; Levine M
Pharmacoecon Open; 2019 Dec; 3(4):437-451. PubMed ID: 31041614
[TBL] [Abstract][Full Text] [Related]
5. The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis.
Zhang W; Guh DP; Grootendorst P; Hollis A; Anis AH
Health Policy; 2024 Jun; 144():105064. PubMed ID: 38608459
[TBL] [Abstract][Full Text] [Related]
6. Generic competition in Canada.
Steele JW
Pharmacoeconomics; 1994 Nov; 6(5):480-2. PubMed ID: 10155276
[TBL] [Abstract][Full Text] [Related]
7. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
Rawson NSB
Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.
Marshall DA; Douglas PR; Drummond MF; Torrance GW; Macleod S; Manti O; Cheruvu L; Corvari R
Pharmacoeconomics; 2008; 26(6):477-95. PubMed ID: 18489199
[TBL] [Abstract][Full Text] [Related]
9. The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study.
Zhang W; Sun H; Guh DP; Grootendorst P; Hollis A; Anis AH
CMAJ; 2024 May; 196(20):E691-E701. PubMed ID: 38802136
[TBL] [Abstract][Full Text] [Related]
10. New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.
Stewart DJ; Bradford JP; Sehdev S; Ramsay T; Navani V; Rawson NSB; Jiang DM; Gotfrit J; Wheatley-Price P; Liu G; Kaplan A; Spadafora S; Goodman SG; Auer RAC; Batist G
Curr Oncol; 2024 Apr; 31(5):2453-2480. PubMed ID: 38785465
[TBL] [Abstract][Full Text] [Related]
11. Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports.
Bloudek LM; Nguyen V; Grueger J; Sullivan SD
Value Health; 2021 Jun; 24(6):789-794. PubMed ID: 34119076
[TBL] [Abstract][Full Text] [Related]
12. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.
Foroutan N; Tarride JE; Xie F; Jameel B; Mills F; Levine M
J Popul Ther Clin Pharmacol; 2020 Jan; 27(1):e1-e24. PubMed ID: 31922700
[TBL] [Abstract][Full Text] [Related]
13. Marketing before patenting: implications for price controls in Canada.
Lexchin J
Open Med; 2010; 4(3):e139-42. PubMed ID: 21687333
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
[TBL] [Abstract][Full Text] [Related]
15. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
Binder L; Ghadban M; Sit C; Barnard K
Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
[TBL] [Abstract][Full Text] [Related]
16. Health Canada's use of its priority review process for new drugs: a cohort study.
Lexchin J
BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
[TBL] [Abstract][Full Text] [Related]
17. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
Shaw B; Mestre-Ferrandiz J
Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
[TBL] [Abstract][Full Text] [Related]
18. Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.
Shah ED; Saini SD; Chey WD
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2687-2695.e11. PubMed ID: 30831219
[TBL] [Abstract][Full Text] [Related]
19. The effect of patented drug price on the share of new medicines across OECD countries.
Spicer O; Grootendorst P
Health Policy; 2022 Aug; 126(8):795-801. PubMed ID: 35654617
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
